David Cunningham

130.4k total citations · 33 hit papers
1.2k papers, 77.9k citations indexed

About

David Cunningham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David Cunningham has authored 1.2k papers receiving a total of 77.9k indexed citations (citations by other indexed papers that have themselves been cited), including 702 papers in Oncology, 452 papers in Pulmonary and Respiratory Medicine and 397 papers in Surgery. Recurrent topics in David Cunningham's work include Colorectal Cancer Treatments and Studies (389 papers), Gastric Cancer Management and Outcomes (320 papers) and Lymphoma Diagnosis and Treatment (161 papers). David Cunningham is often cited by papers focused on Colorectal Cancer Treatments and Studies (389 papers), Gastric Cancer Management and Outcomes (320 papers) and Lymphoma Diagnosis and Treatment (161 papers). David Cunningham collaborates with scholars based in United Kingdom, United States and France. David Cunningham's co-authors include Ian Chau, Timothy Iveson, Eric Van Cutsem, William Allum, Elizabeth Smyth, A. Norman, Naureen Starling, M. Nicolson, Alicia Okines and Andrés Cervantes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Cunningham

1.2k papers receiving 75.9k citations

Hit Papers

Perioperative Chemotherap... 1996 2026 2006 2016 2006 2004 2010 2000 2008 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
    2006 4.5k citations David Cunningham, William Allum et al. profile →
  2. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
    2004 3.9k citations David Cunningham, Yves Humblet et al. profile →
  3. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
    2010 3.0k citations David Cunningham, John Bridgewater et al. profile →
  4. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
    2000 2.5k citations David Cunningham et al. profile →
  5. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
    2008 1.7k citations David Cunningham, Naureen Starling et al. profile →
  6. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    2014 1.7k citations Eric Van Cutsem, G. Bodoky et al. profile →
  7. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
    2011 1.4k citations Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology profile →
  8. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
    2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
  9. Colorectal cancer
    2010 1.1k citations David Cunningham, Naureen Starling et al. profile →
  10. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2010 1.1k citations Alicia Okines, William Allum et al. Annals of Oncology profile →
  11. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2016 1.1k citations Elizabeth Smyth, William Allum et al. Annals of Oncology profile →
  12. The role of probiotics in aquaculture
    2006 1.0k citations David Cunningham et al. profile →
  13. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    1998 973 citations David Cunningham et al. profile →
  14. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
    2009 893 citations Sabine Tejpar, G. Bodoky et al. Journal of Clinical Oncology profile →
  15. Oesophageal cancer
    2017 831 citations Elizabeth Smyth, David Cunningham et al. profile →
  16. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1
    2010 723 citations David Cunningham et al. profile →
  17. Oesophageal cancer
    2017 691 citations Elizabeth Smyth, David Cunningham et al. profile →
  18. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
    1997 691 citations David Cunningham, J.H. Scarffe et al. Journal of Clinical Oncology profile →
  19. Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study
    1998 613 citations Jervoise Andreyev, David Cunningham et al. profile →
  20. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    1998 603 citations Jervoise Andreyev, J. Oates et al. profile →
  21. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    2009 602 citations David Cunningham, Ian Chau et al. Journal of Clinical Oncology profile →
  22. Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin
    1996 581 citations David Cunningham et al. profile →
  23. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
    2013 547 citations Ian Chau, David Cunningham et al. profile →
  24. Guidelines for the management of oesophageal and gastric cancer
    2011 481 citations W H Allum, David Cunningham et al. Gut profile →
  25. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
    2013 459 citations David Cunningham, Mark Saunders et al. profile →
  26. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    2013 438 citations David Cunningham, István Láng et al. profile →
  27. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
    2013 405 citations John Bridgewater, Ian Chau et al. profile →
  28. Mismatch Repair Deficiency, Microsatellite Instability, and Survival
    2017 365 citations Elizabeth Smyth, Andrew Wotherspoon et al. profile →
  29. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    2013 357 citations David Cunningham, Andrew Jack et al. profile →
  30. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
    2017 331 citations David Cunningham et al. profile →
  31. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    2016 328 citations David Cunningham et al. profile →
  32. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    2021 212 citations Peter Johnson, David Cunningham et al. profile →
  33. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    2023 163 citations David Cunningham et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David Cunningham 42.1k 30.7k 24.5k 13.7k 12.7k 1.2k 77.9k
Murray F. Brennan 38.6k 0.9× 43.3k 1.4× 31.6k 1.3× 6.8k 0.5× 5.6k 0.4× 954 81.0k
Jaap Verweij 28.2k 0.7× 22.3k 0.7× 8.8k 0.4× 4.6k 0.3× 13.7k 1.1× 621 55.4k
Josep Tabernero 34.3k 0.8× 14.7k 0.5× 8.1k 0.3× 9.5k 0.7× 14.4k 1.1× 1.1k 50.8k
Charles J. Yeo 42.3k 1.0× 17.4k 0.6× 29.0k 1.2× 3.6k 0.3× 10.8k 0.9× 579 56.1k
Lindsey A. Torre 32.3k 0.8× 23.0k 0.7× 14.4k 0.6× 6.9k 0.5× 35.1k 2.8× 14 93.9k
John L. Cameron 40.4k 1.0× 21.5k 0.7× 35.3k 1.4× 2.0k 0.1× 7.4k 0.6× 531 62.4k
Cornelis J.�H. van de Velde 27.5k 0.7× 14.4k 0.5× 21.3k 0.9× 4.4k 0.3× 5.2k 0.4× 688 47.9k
Charles S. Fuchs 30.0k 0.7× 9.5k 0.3× 9.1k 0.4× 13.5k 1.0× 15.4k 1.2× 721 58.8k
Hyuna Sung 32.2k 0.8× 24.5k 0.8× 11.9k 0.5× 6.0k 0.4× 29.3k 2.3× 84 88.6k
Yoshihiko Maehara 13.5k 0.3× 12.2k 0.4× 14.4k 0.6× 2.9k 0.2× 11.2k 0.9× 1.7k 42.9k

Countries citing papers authored by David Cunningham

Since Specialization
Citations

This map shows the geographic impact of David Cunningham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cunningham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cunningham more than expected).

Fields of papers citing papers by David Cunningham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Cunningham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cunningham. The network helps show where David Cunningham may publish in the future.

Co-authorship network of co-authors of David Cunningham

This figure shows the co-authorship network connecting the top 25 collaborators of David Cunningham. A scholar is included among the top collaborators of David Cunningham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Cunningham. David Cunningham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gordon, Anderley, Martin Davidson, Jane Thompson, et al.. (2024). 1424P Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial. Annals of Oncology. 35. S888–S888. 1 indexed citations
2.
Wirapati, Pratyaksha, Yourae Hong, Leslie Samuel, et al.. (2024). Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial.. Journal of Clinical Oncology. 42(16_suppl). 3592–3592.
3.
Stewart, Adam, et al.. (2020). Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer. Molecular Cancer Research. 18(6). 835–846. 19 indexed citations
4.
Stewart, Adam, Elizabeth A. Coker, Sebastian Pölsterl, et al.. (2019). Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers. Molecular Cancer Therapeutics. 18(8). 1396–1404. 14 indexed citations
5.
6.
Ludman, Peter, Neil Moat, Mark de Belder, et al.. (2015). Transcatheter Aortic Valve Implantation in the United Kingdom. Circulation. 131(13). 1181–1190. 214 indexed citations
7.
Schmoll, Hans‐Joachim, David Cunningham, Alberto Sobrero, et al.. (2012). Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology. 30(29). 3588–3595. 163 indexed citations
8.
9.
Cutsem, Eric Van, Claus-Henning Köhne, István Láng, et al.. (2011). Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology. 29(15). 2011–2019. 1441 indexed citations breakdown →
10.
Douillard, Jean‐Yves, Salvatore Siena, James T. Cassidy, et al.. (2010). Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology. 28(31). 4697–4705. 1351 indexed citations breakdown →
11.
Tebbutt, Niall C., Kate Wilson, Val Gebski, et al.. (2010). Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology. 28(19). 3191–3198. 315 indexed citations
12.
Hoskin, Peter, Lisa Lowry, Alan Horwich, et al.. (2009). Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology. 27(32). 5390–5396. 124 indexed citations
13.
Baldwin, Christine, C. McGough, A. Spiro, et al.. (2009). Nutritional and clinical characteristics of patients with gastrointestinal tract (GI) cancers at presentation. Proceedings of The Nutrition Society. 68(OCE1). 11 indexed citations
14.
Cutsem, Eric Van, Fernando Rivera, Sean L. Berry, et al.. (2009). SAFETY AND EFFICACY OF BEVACIZUMAB (BEV) AND CHEMOTHERAPY IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): RESULTS FROM THE BEAT OBSERVATIONAL COHORT STUDY. UCL Discovery (University College London). 5 indexed citations
15.
Cunningham, David, et al.. (2005). Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). UCL Discovery (University College London). 12 indexed citations
16.
Marcus, Robert, Kevin Imrie, Andrew Belch, et al.. (2003). An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.. Ghent University Academic Bibliography (Ghent University). 34 indexed citations
17.
Thirion, P., Pascal Piedbois, Marc Buyse, et al.. (2001). Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. British Journal of Cancer. 84(5). 611–620. 23 indexed citations
18.
Cunningham, David, et al.. (2000). Irinotecan and infusional 5-fluorouracil as first line treatment of metastatic colorectal cancer: improved survival and cost-effective compared with infusional 5-FU. View. 3 indexed citations
19.
Gisselbrecht, Christian, G Prentice, Almalina Bacigalupo, et al.. (1993). A PHASE-III RANDOMIZED PLACEBO-CONTROLED STUDY IN 315 PEDIATRIC AND ADULT AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LENOGRASTIM-5 UG/KG/DAY (GLYCOSYLATED RHU-G-CSF). UCL Discovery (University College London). 4 indexed citations
20.
Crampton, J R, Luz Gibbons, David Cunningham, et al.. (1986). The British Society of Gastroenterology. 1986 spring meeting. 9-11 April 1986.. Gut. 27(5). A592–A634. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Murray F. Brennan Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Josep Tabernero Breakdown of academic impact, for papers by Charles J. Yeo Breakdown of academic impact, for papers by Lindsey A. Torre Breakdown of academic impact, for papers by John L. Cameron Breakdown of academic impact, for papers by Cornelis J.�H. van de Velde Breakdown of academic impact, for papers by Charles S. Fuchs Breakdown of academic impact, for papers by Hyuna Sung Breakdown of academic impact, for papers by Yoshihiko Maehara
Rankless by CCL
2026